176 related articles for article (PubMed ID: 27435198)
1. Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability.
Ochi M; Kimura K; Kanda A; Kawachi T; Matsuda A; Yuminoki K; Hashimoto N
AAPS PharmSciTech; 2016 Aug; 17(4):932-9. PubMed ID: 27435198
[TBL] [Abstract][Full Text] [Related]
2. Development of nanocrystal formulation of meloxicam with improved dissolution and pharmacokinetic behaviors.
Ochi M; Kawachi T; Toita E; Hashimoto I; Yuminoki K; Onoue S; Hashimoto N
Int J Pharm; 2014 Oct; 474(1-2):151-6. PubMed ID: 25138254
[TBL] [Abstract][Full Text] [Related]
3. Amorphous Solid Dispersion of Meloxicam Enhanced Oral Absorption in Rats With Impaired Gastric Motility.
Suzuki H; Yakushiji K; Matsunaga S; Yamauchi Y; Seto Y; Sato H; Onoue S
J Pharm Sci; 2018 Jan; 107(1):446-452. PubMed ID: 28551427
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability.
Onoue S; Kojo Y; Aoki Y; Kawabata Y; Yamauchi Y; Yamada S
Drug Metab Pharmacokinet; 2012; 27(4):379-87. PubMed ID: 22240843
[TBL] [Abstract][Full Text] [Related]
5. Characterization and stability of solid dispersions based on PEG/polymer blends.
Bley H; Fussnegger B; Bodmeier R
Int J Pharm; 2010 May; 390(2):165-73. PubMed ID: 20132875
[TBL] [Abstract][Full Text] [Related]
6. Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach.
Onoue S; Sato H; Ogawa K; Kawabata Y; Mizumoto T; Yuminoki K; Hashimoto N; Yamada S
Int J Pharm; 2010 Oct; 399(1-2):94-101. PubMed ID: 20705124
[TBL] [Abstract][Full Text] [Related]
7. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.
Chavan RB; Lodagekar A; Yadav B; Shastri NR
Drug Deliv Transl Res; 2020 Aug; 10(4):903-918. PubMed ID: 32378174
[TBL] [Abstract][Full Text] [Related]
8. Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation.
Weyna DR; Cheney ML; Shan N; Hanna M; Zaworotko MJ; Sava V; Song S; Sanchez-Ramos JR
Mol Pharm; 2012 Jul; 9(7):2094-102. PubMed ID: 22642304
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions.
Andrews GP; AbuDiak OA; Jones DS
J Pharm Sci; 2010 Mar; 99(3):1322-35. PubMed ID: 19798757
[TBL] [Abstract][Full Text] [Related]
10. Drug-polymer miscibility, interactions, and precipitation inhibition studies for the development of amorphous solid dispersions for the poorly soluble anticancer drug flutamide.
Trivino A; Gumireddy A; Meng F; Prasad D; Chauhan H
Drug Dev Ind Pharm; 2019 Aug; 45(8):1277-1291. PubMed ID: 31111732
[TBL] [Abstract][Full Text] [Related]
11. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
12. Development of meloxicam salts with improved dissolution and pharmacokinetic behaviors in rats with impaired gastric motility.
Ochi M; Inoue R; Yamauchi Y; Yamada S; Onoue S
Pharm Res; 2013 Feb; 30(2):377-86. PubMed ID: 22983645
[TBL] [Abstract][Full Text] [Related]
13. Stabilization of a supersaturated solution of mefenamic acid from a solid dispersion with EUDRAGIT(®) EPO.
Kojima T; Higashi K; Suzuki T; Tomono K; Moribe K; Yamamoto K
Pharm Res; 2012 Oct; 29(10):2777-91. PubMed ID: 22219167
[TBL] [Abstract][Full Text] [Related]
14. Mid-infrared spectroscopy as a polymer selection tool for formulating amorphous solid dispersions.
Wegiel LA; Mauer LJ; Edgar KJ; Taylor LS
J Pharm Pharmacol; 2014 Feb; 66(2):244-55. PubMed ID: 24433425
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion.
Metre S; Mukesh S; Samal SK; Chand M; Sangamwar AT
Mol Pharm; 2018 Feb; 15(2):652-668. PubMed ID: 29287144
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinylpyrrolidone K-30.
El-Badry M; Fathy M
Drug Dev Ind Pharm; 2006 Feb; 32(2):141-50. PubMed ID: 16537195
[TBL] [Abstract][Full Text] [Related]
17. Investigation and correlation of physical stability, dissolution behaviour and interaction parameter of amorphous solid dispersions of telmisartan: a drug development perspective.
Dukeck R; Sieger P; Karmwar P
Eur J Pharm Sci; 2013 Jul; 49(4):723-31. PubMed ID: 23684913
[TBL] [Abstract][Full Text] [Related]
18. Eudragit EPO nanoparticles: application in improving therapeutic efficacy and reducing ulcerogenicity of meloxicam on oral administration.
Khachane P; Date AA; Nagarsenker MS
J Biomed Nanotechnol; 2011 Aug; 7(4):590-7. PubMed ID: 21870464
[TBL] [Abstract][Full Text] [Related]
19. Amorphous solid dispersion of cyclosporine A prepared with fine droplet drying process: Physicochemical and pharmacokinetic characterization.
Suzuki H; Moritani T; Morinaga T; Seto Y; Sato H; Onoue S
Int J Pharm; 2017 Mar; 519(1-2):213-219. PubMed ID: 28093327
[TBL] [Abstract][Full Text] [Related]
20. An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β-cyclodextrin.
Bandarkar FS; Vavia PR
Drug Dev Ind Pharm; 2011 Nov; 37(11):1318-28. PubMed ID: 21506882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
